Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center

Main Category: Cancer / Oncology
Also Included In: Breast Cancer;  Medical Devices / Diagnostics
Article Date: 12 Sep 2008 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:5 stars

5 (1 votes)


The Advalytix product team of Olympus is initiating a collaborative study with The University of Texas M. D. Anderson Cancer Center to characterize circulating tumor cells in breast cancer patients.

The study combines Advalytix's sensitive AmpliGrid molecular analysis platform, multiplex primer design, and integrated workflow to analyze expression of multiple target genes in single tumor cells.

"Using AmpliGrid, we plan to genetically fingerprint subpopulations of tumor cells with a convenient workflow," said Dr. James Reuben, Associate Professor at M. D. Anderson Cancer Center.

"The goal is to develop powerful tools to monitor the response to treatment, improve early detection, and personalize treatment for our patients," added Dr. Massimo Cristofanilli, M.D., Associate Professor in the Department of Breast Medical Oncology at M. D. Anderson.

The Advalytix AmpliGrid single-cell molecular analysis platform allows the M. D. Anderson team to measure heterogeneity by comparing the genetic profiles of individual tumor cells. Establishing the clinical relevance of heterogeneity requires studying a large number of clinical specimens. AmpliGrid meets these throughput requirements with a simple workflow that seamlessly integrates the steps needed for each clinical specimen, namely: cell sorting, sample preparation, and PCR.

About Breast Cancer

Breast cancer is the most common malignancy in women, and is the second leading cause of cancer death. A heterogeneous disease, the incidence of breast cancer has increased steadily since 1960. Each year 200,000 new cases of breast cancer are diagnosed, and over 40,000 patients die from the disease (data from http://www.thebreastcancersite.com).

About Advalytix

Advalytix is Olympus' worldwide competence centre for cell-based molecular biology, with a focus on single cell molecular diagnostics, and the miniaturization of diagnostic and biological tests for research and development. Advalytix products uniquely link imaging technologies such as microscopy with nucleic acid analysis, enabling turnkey solutions with optimized instruments and reagents.

Advalytix

Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Advalytix. "Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center." Medical News Today. MediLexicon, Intl., 12 Sep. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/121256.php>

APA
Advalytix. (2008, September 12). "Advalytix Announces Study Of Single Circulating Tumor Cells With The M. D. Anderson Cancer Center." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/121256.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »